מלטה - אנגלית - Medicines Authority

accord healthcare limited - pravastatin sodium - tablet - pravastatin sodium 20 mg - lipid modifying agents

מלטה - אנגלית - Medicines Authority

accord healthcare limited - pravastatin sodium - tablet - pravastatin sodium 40 mg - lipid modifying agents

מלטה - אנגלית - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - pravastatin sodium - tablet - pravastatin sodium 10 mg - lipid modifying agents

מלטה - אנגלית - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - pravastatin sodium - tablet - pravastatin sodium 20 mg - lipid modifying agents

מלטה - אנגלית - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - pravastatin sodium - tablet - pravastatin sodium 40 mg - lipid modifying agents

ארצות הברית - אנגלית - NLM (National Library of Medicine)

sandoz inc - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets are indicated to: pravastatin sodium tablets are indicated: pravastatin sodium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (fredrickson types i and v). hypersensitivity to any component of this medication. active liver disease or unexplained, persistent elevations of serum transaminases [see warnings and precautions (5.2) ] . atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy shoul

ארצות הברית - אנגלית - NLM (National Library of Medicine)

major pharmaceuticals - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets are indicated to: in patients with clinically evident chd, pravastatin sodium is indicated to: pravastatin sodium tablets are indicated: pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (fredrickson types i and v). hypersensitivity to any component of this medication. active liver disease or unexplained, persistent elevations of serum transaminases [see warnings and precautions (5.2) ]. atherosclerosis is a chronic process and di

ארצות הברית - אנגלית - NLM (National Library of Medicine)

cardinal health 107, llc - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablets are indicated to: in patients with clinically evident chd, pravastatin sodium tablets are indicated to: pravastatin sodium tablets are indicated: pravastatin sodium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( fredrickson types i and v). hypersensitivity to any component of this medication. active liver disease or unexplained, persistent elevations of serum transaminases [ see warnings and precautions (

ישראל - אנגלית - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - tablets - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute co

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

advantage medical products consulting pty ltd - pitavastatin calcium, quantity: 4.18 mg (equivalent: pitavastatin, qty 4 mg) - tablet, film coated - excipient ingredients: aluminium magnesium silicate; lactose monohydrate; hypromellose; triethyl citrate; magnesium stearate; hyprolose; titanium dioxide; colloidal anhydrous silica - livalo is indicated as an adjunct to diet for the treatment of adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, when response to diet and other non-pharmacological measures is inadequate. prior to initiating therapy with livalo, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.